Effect of Citrulline on the Clinical and Biochemical Evolution of Patients With Sepsis. (CITRUSEP)
Sepsis
About this trial
This is an interventional treatment trial for Sepsis focused on measuring sepsis, citrulline, endothelial, toxemia, endothelial determination of progression, with vs without citrulline
Eligibility Criteria
Inclusion Criteria:
- Sepsis
- Severe sepsis
- Diagnosis of sepsis in the first 36 hours of hospitalization.
- Informed Consent
- Intestinal tract intact
Exclusion Criteria:
- Terminal cancer
- Acute and chronic liver diseases
- Chronic renal failure.
- Acute renal failure AKIN III.
- Pregnant and postpartum women
- Dying patients.
- Patients with cardiac arrest.
- Active gastrointestinal bleeding.
- Steroids or immunosuppressants.
- Enrolled in another study intervention.
- Citrulline allergy.
Sites / Locations
- CME Centro Mèdico Siglo XXIRecruiting
- CME La RazaRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Intervention
Placebo
Oral or nasogastric administration of 10 g citrulline malate daily. Blood and urine samples to determine biomarkers of endothelial damage (IL 6, IL 10 , nitric oxide and microalbuminuria), with a second sampling after 7 days of intervention. Disease severity will be measure with various scales, including APACHE II, SOFA
10 g of maltodextrin will be substituted for the citrulline. Blood and urine samples to determine biomarkers of endothelial damage (IL 6, IL 10 , nitric oxide and microalbuminuria), with a second sampling after 7 days of intervention. Disease severity will be measure with various scales, including APACHE II, SOFA